公司简介
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizu...
关联新闻
- Supernus, Indivior merge to strengthen neuroscience drug portfolio
Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of m...